#aurbindopharma - Twitter Hashtag

Devang

@dev_1973

5 months ago

#result #nseindian #bseindia #nifty #sensec #itc #aurbindopharma #mtnl #gail #icra #rcf #proteanegov

0

2

0

410

Informist Media

@InformistMedia

about 1 year ago

#AurbindoPharma Ltd. said its US business remained resilient and they see no decline in the demand in the US for its base business, despite uncertainties around US #Tariffs throughout the June quarter. Click here to read more: https://t.co/llJJp7CF9x

0

2

0

138

Stocking The Stocks @stock_stalekr07

about 1 year ago

#Stocks in #News 05/08/25- #BEML- Bags 282 Cr order from MoD #IndusindBank- Rajiv Anand New MD & CEO #Paytm- Alibaba 3800Cr block deal #AurbindoPharma- Subdued number #PremierExplosives-190Cr export order #NSDL-Allotment #SiemensEnergy-Very Good Result #InoxIndia- Good Result

stock_stalekr07's tweet photo. #Stocks in #News 05/08/25-

#BEML- Bags 282 Cr order from MoD
#IndusindBank- Rajiv Anand New MD & CEO
#Paytm- Alibaba 3800Cr block deal
#AurbindoPharma- Subdued number
#PremierExplosives-190Cr export order
#NSDL-Allotment
#SiemensEnergy-Very Good Result
#InoxIndia- Good Result https://t.co/LON1r5Qqps

0

2

1

0

562

PaisaPani @PaisaPani

over 1 year ago

ऑरबिंदो फार्मासाठी धोक्याची घंटा! #aurbindo #aurbindopharma #fda #pharmaindustry #Sharemarket #finance #Paisapani #म #मराठी

0

16

1

0

841

NewsCapital Gujarat

@NewsCapitalGJ

over 1 year ago

EXPERT BULLISH ON THIS STOCK | SHORT TERM AND LONG TERM INVESTMENT | TARGET UPDATES કવન પટેલ તરફથી આ શેર પર ખરીદી કરવાની સલાહ આપવામાં આવી.. #Ramco #Aurbindopharma #Business #Investment #Stock #Stocks #Stockmarket

0

1

0

263

ASSURE ☺☺ @SapnaVe88782185

about 2 years ago

Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore. #Aurbindopharma

0

2

0

81

ETMarkets

@ETMarkets

about 2 years ago

Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore. #Aurbindopharma https://t.co/hOKK8SJpl6

0

3

0

1K

Shivani Ghildiyal @ShivaniGhildyal

over 2 years ago

What the hell is happening #AurbindoPharma #BhartiAirtel #KotakGroup #ElectoralBondScam

Supriya Sharma

@sharmasupriya

over 2 years ago

#BREAKING A Kotak firm donated Rs 60 crore to the BJP The donations coincided with crucial RBI decisions related to Uday Kotak’s stake and tenure in the Kotak Mahindra bank @sighyush and #ProjectElectoralBond https://t.co/aHY4tFpQHn

61

3K

2K

58

83K

0

2

0

167

Abhash Raj Chandela

@AbhashChandela

over 2 years ago

#AurbindoPharma से 50 करोड़ का माल लें भाजपा के दलाल, और जेल जाएं @ArvindKejriwal #IStandWithKejriwal #MainBhiKejriwal

0

11

6

0

136

Quint Hindi

@QuintHindi

over 2 years ago

दिल्ली शराब नीति मामले में 'सरकारी गवाह' बने आरोपी सरथ रेड्डी की कंपनी से बीजेपी को इलेक्टोरल बॉन्ड के जरिए कुल मिलाकर ₹34 करोड़ का चंदा मिला है. #BJP #aurbindopharma

2

24

8

1

693

Ravi Srivastava🇮🇳रविश्रीवास्तव🐤(INDIA वाले)

@ravi4354

over 2 years ago

#DelhiLiquorScam there was a #SarathReddy raided by @dir_ed for his involvement in above scam,he was connected to #AurbindoPharma he bought 5cr₹ #ElectoralBonds within 6mnths he got bail on Health ground,became approver&bought more₹25cr Bonds Guest which party he donated ?🤔

1

4

5

0

295

CA Tejas Gaikwad @trustnshine

almost 3 years ago

#casestudy #Aurbindopharma This pharma stock is all set for breaking the consolidation zone of long 10 years. Chart is telling big story itself 😍 Looks like will easily achieve the target of 1500 & 1750. The Conall For Q2 2023 was quite interesting. Read the notes below 🎯Financial Performance: 👉Aurobindo Pharma reported highest ever sales and highest EBITDA in the past 12 quarters. 👉Revenue for Q2 FY24 was Rs. 7,219 crores, with a YoY increase of 25.8%. 👉EBITDA before forex and other income grew by 67.7% YoY and by 21.9% QoQ to Rs. 1,403 crores. 👉Net profit increased by 83.6% YoY and by 31.7% QoQ to Rs. 752 crores. 🎯Business Segments: 👉Formulation business witnessed a growth of 29% YoY and contributed around 82.7% to total revenue. 👉API business contributed around 16.2% and clocked a revenue of Rs. 1,166 crores, a YoY growth of 20.3%. 👉Revenue from U.S. formulations without Puerto Rico increased by 35.7% YoY to Rs. 3,385 crores. 👉The company has received final approval for 15 ANDAs and launched 19 products in Q2 FY24. 👉Aurobindo Pharma USA's revenue increased by 23.3% YoY to USD 212 million in Q2 FY24. 👉The European formulation business clocked a revenue of Rs. 1,769 crores, a YoY growth of 16.7%. 👉The growth market revenue increased by 24.7% YoY to Rs. 564 crores. 🎯Guidance and Future Growth: 👉The company expects to achieve a 20% plus EBITDA margin target for the year. 👉New projects and partnerships, such as the biologics CDMO business and the acquisition of market authorizations, are expected to drive future growth and margins. 👉The company is focused on biosimilars and peptides as significant growth drivers. 👉The CAPEX for generics will be focused on debottlenecking, additional lines, and maintenance to increase manufacturing capacity and efficiency. 👉The company is confident about its future outlook and committed to strong execution. https://t.co/7vl3S7zJMQ #StocksToBuy #stockstowatch #StocksInFocus #nifty50 #StocksToTrade #StocksInNews #expiry #midcapnifty #banknifty #options #finnifty #NiftyBank

trustnshine's tweet photo. #casestudy #Aurbindopharma

This pharma stock is all set for breaking the consolidation zone of long 10 years.

Chart is telling big story itself 😍

Looks like will easily achieve the target of 1500 & 1750.

The Conall For Q2 2023 was quite interesting. Read the notes below

🎯Financial Performance:

👉Aurobindo Pharma reported highest ever sales and highest EBITDA in the past 12 quarters.

👉Revenue for Q2 FY24 was Rs. 7,219 crores, with a YoY increase of 25.8%.

👉EBITDA before forex and other income grew by 67.7% YoY and by 21.9% QoQ to Rs. 1,403 crores.

👉Net profit increased by 83.6% YoY and by 31.7% QoQ to Rs. 752 crores.

🎯Business Segments:

👉Formulation business witnessed a growth of 29% YoY and contributed around 82.7% to total revenue.

👉API business contributed around 16.2% and clocked a revenue of Rs. 1,166 crores, a YoY growth of 20.3%.

👉Revenue from U.S. formulations without Puerto Rico increased by 35.7% YoY to Rs. 3,385 crores.

👉The company has received final approval for 15 ANDAs and launched 19 products in Q2 FY24.

👉Aurobindo Pharma USA's revenue increased by 23.3% YoY to USD 212 million in Q2 FY24.

👉The European formulation business clocked a revenue of Rs. 1,769 crores, a YoY growth of 16.7%.

👉The growth market revenue increased by 24.7% YoY to Rs. 564 crores.

🎯Guidance and Future Growth:

👉The company expects to achieve a 20% plus EBITDA margin target for the year.

👉New projects and partnerships, such as the biologics CDMO business and the acquisition of market authorizations, are expected to drive future growth and margins.

👉The company is focused on biosimilars and peptides as significant growth drivers.

👉The CAPEX for generics will be focused on debottlenecking, additional lines, and maintenance to increase manufacturing capacity and efficiency.

👉The company is confident about its future outlook and committed to strong execution.

https://t.co/7vl3S7zJMQ

#StocksToBuy #stockstowatch #StocksInFocus #nifty50 #StocksToTrade #StocksInNews #expiry #midcapnifty #banknifty #options #finnifty #NiftyBank

0

7

2

1K

Anirban (Derivative Certified)

@Anirbban

almost 3 years ago

If you are holding it is your study and reason. You are trying to copy, without understanding. This is not the intention of this community. Try to be self-dependent & take your own decision. Anyhow I gave update long back. #AurbindoPharma. https://t.co/N4Y4um8sMd

Anirban (Derivative Certified)

@Anirbban

almost 3 years ago

Many of you guessed it right.. It's #AurbindoPharma.. 🤞 #OptionsTrading

5

53

6

2

21K

0

2

0

630

Anirban (Derivative Certified)

@Anirbban

almost 3 years ago

Many of you guessed it right.. It's #AurbindoPharma.. 🤞 #OptionsTrading

Anirban (Derivative Certified)

@Anirbban

almost 3 years ago

A #pharma stock can give breakout which I am studying.. You guys don't appreciate a good study.. In last 20-25 studies I think more than 95% went to right direction. Let me focus on my research and see if I can post an EOD profit screenshot or not.. Not an advice, pls do your own research. #OptionsTrading

Anirbban's tweet photo. A #pharma stock can give breakout which I am studying..

You guys don't appreciate a good study..

In last 20-25 studies I think more than 95% went to right direction.

Let me focus on my research and see if I can post an EOD profit screenshot or not..

Not an advice, pls do your own research.

#OptionsTrading

49

164

12

62K

5

53

6

2

21K

NDTV Profit Alpha

@NDTVProfitAlpha

about 3 years ago

#Lupin, #AurbindoPharma, #Cipla all have one thing in common: Brokerages have them as their top picks. But the question is why? @SanghviMonal reports. https://t.co/kzh4yhpYdF

0

4

1

0

2K

NDTV Profit Alpha

@NDTVProfitAlpha

about 3 years ago

#AurbindoPharma unit gets U.S. FDA approval for Icatibant injection. For the latest news and updates, visit: https://t.co/gXeGqKQ77P

NDTVProfitAlpha's tweet photo. #AurbindoPharma unit gets U.S. FDA approval for Icatibant injection.

For the latest news and updates, visit: https://t.co/gXeGqKQ77P https://t.co/H5nmimeD26

0

1K

ET NOW

@ETNOWlive

about 3 years ago

Stocks In News | USFDA finishes inspection of Aurbindo Pharma's Eugia plant @US_FDA #AurbindoPharma

0

4

0

2K

Free Press Journal

@fpjindia

over 3 years ago

Aurobindo Pharma's subsidiary receives USFDA approval for manufacturing Lenalidomide Capsules #aurbindopharma #usfda #eugia #BusinessNews https://t.co/kbdQMgR9Zx

0

2

0

230